First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
about
Adjuvant therapy for pancreas cancer in an era of value based cancer careNext-generation prognostic assessment for diffuse large B-cell lymphomaBevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries.Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice.Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World.Update on Anti-Angiogenesis Therapy in Colorectal Cancer.Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial.Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer.Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.The high price of anticancer drugs: origins, implications, barriers, solutions.Economics of ramucirumab for metastatic colorectal cancer.Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland.Linking the Price of Cancer Drug Treatments to Their Clinical Value.Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.The cost and value of cancer drugs - are new innovations outpacing our ability to pay?Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.A global comparison of the cost of patented cancer drugs in relation to global differences in wealth.Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives.Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.Financial toxicity and implications for cancer care in the era of molecular and immune therapies.Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer
P2860
Q26775916-88655206-0445-4C64-88F4-D76E2BC23D68Q26796428-D6ECD500-8839-4995-B449-6EF2E7ECCF74Q33859790-0A8BFF4D-6542-487B-90DD-8632457F8932Q35754399-1C123193-2A53-4758-8DD2-702A940D508DQ36286084-3C47734B-0F01-4B86-8A4B-1BCAACF09FFAQ36553713-4514CE05-01C2-4D7A-8610-FC81D91BCFA0Q37066657-66174B60-CF2D-4BFE-A802-68DE80B010E3Q37135340-23FE8F59-FEDE-429B-BF6E-D81AAFB54985Q37157946-139B76F2-027D-4435-9042-062EBE316247Q37162297-BD88D017-C13D-4B3C-BBB2-11239174C601Q37190578-7B02921F-6262-47DD-8813-719E9AF431BBQ37327850-6BBD6720-FC59-46B9-BFFE-4D23B7136F47Q37406803-C5DCE16C-8E45-49C3-ABF1-D45719EC2E09Q38737493-DDD8E58F-274A-42A9-9DE1-0811F2013643Q38792651-1DE06EED-9C83-4AE5-8858-C310D03C2D5EQ38848793-3E013B0F-5B04-404D-9842-72E75C4486DFQ38909657-C1738642-BD4A-4C5F-8605-305702EC5841Q39003764-F2CB79BF-20A4-473E-9501-608898FAA500Q39015252-BCED06EA-065C-4CBE-955F-15165CE27B18Q39453613-ABA92BF4-AA67-4623-8588-EBEDE384872DQ39583831-C9044199-CE03-4B33-94E5-A436B538E00AQ39787879-0544C651-DEB1-4B6A-B73D-A87895726C4AQ40149586-2FBCB25D-B1C3-4A51-97AE-ABFB5FE4A871Q41918758-EA416397-D756-4577-9695-37ACE35ABCFAQ42076362-FFB34ED9-A62B-4CD7-A5A3-F54468CEFDF5Q42392412-36437A7D-5EE9-497C-81D4-0D6C017976B4Q42682716-84ACDA53-890D-4133-B72E-3F7E01622677Q42700925-3FACF00A-8600-4DD3-8D5E-58EC239F19F0Q46446983-AB65BB1F-C04C-4235-8F9E-72FA55042142Q47414479-B60E19C8-9B55-4DDF-97E7-AC9DF14E39A6Q51096441-25C651AE-E654-421C-AFF8-12841D505D04Q51284885-ECA48463-BAFF-41B9-92D1-12D5797D6673Q55265302-AB5FC3B4-4499-421F-BB99-D2288371CF4EQ57152512-38A13C29-BE30-4505-AB61-9C47830F55CA
P2860
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
First- and second-line bevaciz ...... d cost-effectiveness analysis.
@ast
First- and second-line bevaciz ...... d cost-effectiveness analysis.
@en
type
label
First- and second-line bevaciz ...... d cost-effectiveness analysis.
@ast
First- and second-line bevaciz ...... d cost-effectiveness analysis.
@en
prefLabel
First- and second-line bevaciz ...... d cost-effectiveness analysis.
@ast
First- and second-line bevaciz ...... d cost-effectiveness analysis.
@en
P2093
P2860
P921
P356
P1476
First- and second-line bevaciz ...... d cost-effectiveness analysis.
@en
P2093
Bassel F El-Rayes
Christopher R Flowers
Daniel A Goldstein
David H Howard
Joseph Lipscomb
Qiushi Chen
Turgay Ayer
P2860
P304
P356
10.1200/JCO.2014.58.4904
P407
P577
2015-02-17T00:00:00Z